Roche Cobas® Analyzer

For Fully Automated, Electrochemiluminescence (ECL)-Based Immunoassays

Designed for both quantitative and qualitative in vitro assay determinations, BioAgilytix uses the Roche Cobas® e 411 analyzer to support immunoassay analysis for a broad range of applications – from biomarker work to infectious disease testing. The analyzer’s ECL technology yields high sensitivity, reliable, and reproducible results for heterogeneous immunoassays.


Learn more about the cobas analyzer:

Still have questions?

BioAgilytix’s experts are here to help. Let’s schedule a conversation to review your questions and requirements with one of our scientists.


The Roche e 411 Cobas analyzer employs ECL technology to detect extremely low levels of antigen, yielding high sensitivity and the ability to detect subtle changes in antigen levels. Innovative tests can therefore be run using less sample volume, and reagents are protected from external influences to enhance their durability and stability.

The Cobas also provides a wide measuring range which reduces the need to dilute and repeat samples, and minimizes the amount of tests that need to be rerun due to out-of-range results.


BioAgilytix’s scientists utilize the Cobas e 411 analyzer for immunological analysis of serum or plasma, and can support the entire menu of 100+ Elecsys® assays including those for cardiac, bone, and tumor markers, anemia, coagulation, endocrinology, fertility, hepatology, inflammation, and infectious diseases. In particular, we support the FDA Emergency Authorized Use (EUA)-approved Elecsys Anti-SARS-CoV-2 immunoassay for the qualitative detection of antibodies to SARS-CoV-2.

The analyzer’s fully automated intelligent sample workflow supports high throughout, with the ability to run up to 18 assays at a rate of up to 86 tests per hour. The system also features STAT sample positions to allow for immediate emergency testing when needed.

Speak To A Scientist

    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.